Short answer
Lilly (Eli) (LLY) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $17.6B (up 53.9% year over year) with net income of $5.6B.
Q3 2025 key financials · XBRL
- Revenue
- $17.6B
- +53.9% YoY · +13.1% QoQ
- Net income
- $5.6B
- +475.3% YoY · −1.4% QoQ
- EPS (diluted)
- $6.21
- +480.4% YoY · −1.3% QoQ
Source: XBRL data from the Lilly (Eli) (LLY) Q3 2025 10-Q on SEC EDGAR. USD.
Lilly (Eli) Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash and cash equivalents $9.79B as of Sept 30, 2025 vs $3.27B at Dec 31, 2024
- Total debt $42.51B as of Sept 30, 2025, up $8.86B from $33.64B at Dec 31, 2024
- Capital expenditures and contract manufacturing agreements increased for capacity expansion, risking $9B in minimum purchase commitments
- Share repurchases $2.60B YTD under $15B program; $12.40B remaining as of Sept 30, 2025
- No updated revenue, profit, or margin data presented; management notes foreign exchange, economic environment, and geopolitical risks impacting outlook
Risk Factors
- New litigation charge from acquisition of Verve triggered asset impairment and restructuring charges of $365M for Q3 2025, up from $82M prior year
- Effective tax rate decreased to 22.8% in Q3 2025 from 38.9% in Q3 2024, impacted by lower non-deductible acquired IPR&D charges
- Litigation charge and acquisition/integration costs of Verve represent most impactful legal risk affecting operational costs
- Revenue growth driven by strong volume increase in Mounjaro (+109%) and Zepbound (+185%) reflecting competitive market demand
- Cash and equivalents, operating cash flow, and borrowings sufficient to fund capital requirements, maintaining liquidity position
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lilly (Eli) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.